Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.

Abstract: At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

Abstract: Disclosed herein are methods for inhibiting growth of oral pathogenic bacteria and alleviating an oral pathogenic bacteria-associated disorder using a culture of at least one lactic acid bacterial strain selected from the group consisting of Lactobacillus rhamnosus MP108 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 21225, and Lactobacillus paracasei MP137 which is deposited at the CGMCC under an accession number CGMCC 21224.

Abstract: Methods for synthesizing and using R-hydroxynitrile lyase derived from mango. Specifically, a variety of mutant cyanohydrin lyases were obtained by mutating a wild-type hydroxynitrile lyase gene, adding an enzyme cleavage site thereto, preparing a recombinant plasmid by inserting the mutated wild-type hydroxynitrile lyase gene into a vector, introducing the recombinant plasmid into a strain of bacteria, and secreting and expressing the R-hydroxynitrile lyase in the strain. The method Is safe, simple and easy to operate.

Abstract: Disclosed herein are methods for reducing purine content in an edible material and alleviating a disorder of uric acid metabolism using Lactobacillus plantarum TSP05 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 16710.

Abstract: The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, ca

Abstract: The present invention aims to provide a method which has not been established yet and which is useful for achieving long-term and fundamental cure of a necrotic cardiac tissue region to allow recovery of functionality of the heart. The present invention provides an injectable composition for treatment of a cardiac disease, the composition comprising fibroblasts, wherein the fibroblasts contain CD106-positive fibroblasts, preferably contain CD90-positive fibroblasts, and the fibroblasts do not form colonies.

Abstract: The invention relates to a method for high throughput screening compounds by using a plurality of automated cell based assays assessing skeletal muscle cells contractility, morphology, and metabolism, in order to predict the efficacy of said compound on a panel of applications linked with muscle physiological and pathophysiological processes, comprising: (i) providing an in vitro culture of myotubes, wherein the in vitro myotubes culture is obtained by the following method: providing a cell culture device allowing the culture of myoblasts or myotubes, depositing said cells from a human donor or human group of donors, in good health or affected by a muscle related disorder, from primary cells, a cell line, an isogenic cell line or differentiated stem cells recapitulating a muscle disorder, on said culture device by using a method allowing the spatial control of cell culture, culturing said cells during a determined incubation time so as to promote a spatially controlled myotube culture; (ii) adding at least on

Abstract: The present invention describes a process for preparing ultrapure (?95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving Saccharomyces cerevisiae and Streptococcus thermophilus.

Abstract: The present invention in general relates to the field of biological crop protection by use of phytoseiid predatory mites. More particularly the present invention relates to a system for releasing a phytoseiid predatory mite in a crop and novel uses of host mites in such phytoseiid predatory mite releasing system. The phytoseiid predatory mite releasing system according to the invention and the uses according to the invention are characterised by the selection a host mite species having an intrinsic growth rate (rm) of <0.28.

Abstract: The present invention relates to a formulation to stabilize lignocellulolytic enzyme mixture. This invention in particular relates to a formulation composed of lignocellulolytic enzyme with critical dosages of molasses either with petrochemical waste or glycerol as an additive to improve enzyme stability in a synergistic manner.

Abstract: The present application relates to methods for producing materials having viable micro-organisms incorporated therein. More particularly, the materials are produced under high temperature and/or high pressure conditions, and the micro-organisms are incorporated in the material before or during these conditions. Also provided are micro-organisms that remain viable under these conditions and have different applications, depending on the nature of the material.

Abstract: The presently disclosed subject matter provides an approach to address the needs for microscale control in shaping the spacial geometry and microarchitecture of 3D collagen hydrogels. For example, the disclosed subject matter provides for compositions, methods, and systems employing N-sulfosuccinimidyl-6-(4?-azido-2?-nitro-phenylamino)hexanoate (“sulfo-SANPAH”), to prevent detachment of the hydrogel from the anchoring substrate due to cell-mediated contraction.

Abstract: A protein crosslinker delivery device includes a body and a protein crosslinker held in a synthetic or natural biodegradable polymer. The body, a coating on the body, or an attachment to the body can contain the protein crosslinker holding biodegradable polymer. The release rate of the crosslinker and total amount of crosslinker released can be controlled by varying the concentration of the crosslinker and by varying the composition and structural characteristics of the degradable polymer. Surface eroding, bulk eroding and naturally occurring biodegradable polymers can be used in conjunction with a variety of nontoxic or minimally-toxic protein crosslinking agents. The devices can be used to treat mechanically damaged, deformed, and nutritionally deficient connective or soft tissues such as the knee meniscus, the spinal disc, the cornea, ligaments and tendons, the soft palate, and skin.

Abstract: The present invention is directed to enzyme based methods for removing water insoluble non-starch polysaccharides (NSPs) and/or water soluble or insoluble oligosaccharides from soy products without significantly damaging the proteins contained therein This removal is facilitated by the enzymatic hydrolysis of poly- and oligomeric carbohydrates into monosaccharides and other water soluble sugars. The present invention provides for the production of three streams of useful materials. The first is an enriched protein material comparable to the known SPCs but without significant quantities of undigestible oligosaccharides and polysaccharides. The second is an SPI made from the soluble protein in the hydrolysate which is valuable for high-quality feed, food and industrial uses. The third is the soluble saccharides and hydrolyzed carbohydrates (releasing sugars) that can be converted by fermentation to various valuable bioproducts.

Abstract: A method is disclosed of predicting cancer patient response to immune checkpoint inhibitors, e.g., an antibody drug blocking ligand activation of programmed cell death 1 (PD-1) or CTLA4. The method includes obtaining mass spectrometry data from a blood-based sample of the patient, obtaining integrated intensity values in the mass spectrometry data of a multitude of pre-determined mass-spectral features; and operating on the mass spectral data with a programmed computer implementing a classifier. The classifier compares the integrated intensity values with feature values of a training set of class-labeled mass spectral data obtained from a multitude of melanoma patients with a classification algorithm and generates a class label for the sample. A class label “early” or the equivalent predicts the patient is likely to obtain relatively less benefit from the antibody drug and the class label “late” or the equivalent indicates the patient is likely to obtain relatively greater benefit from the antibody drug.

Abstract: The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.

Abstract: An object of the present invention is to provide a cell structure which can be produced within a short period of time and has a predetermined or larger size, and a method for producing the above-described cell structure.

Abstract: The present invention relates to a method for identifying and/or characterising an endophyte strain, said method including providing a plurality of samples of endophytes, subjecting said endophytes to genetic analysis; subjecting said endophytes to metabolic analysis and selecting endophytes having a desired genetic and metabolic profile. The present invention also relates to novel endophytes having a desired toxin profile wherein the endophyte produces significantly less toxic alkaloids compared with a control endophyte such as standard toxic (ST) endophyte; and/or significantly more alkaloids conferring beneficial properties compared with a control endophyte such as ST endophyte. The present invention also relates to endophyte variants having a desired genetic and metabolic profile, wherein said endophyte variants possess genetic and/or metabolic characteristics that result in a beneficial phenotype in a plant harbouring or otherwise associated with the endophyte variant.